Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the
Company"), a biopharmaceutical Company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers,
announced that the first patient was successfully treated with Actimab-A
drug candidate manufactured with the new lot of Lintuzumab, the antibody
that provides the backbone for Actimab-A. The ongoing Phase 1/2 trial of
Actimab-A is in newly diagnosed AML patients over the age of 60 in a
single arm multicenter trial.
"This is another important step forward for Actinium Pharmaceuticals,"
said Dr. Kaushik Dave, the President and CEO of Actinium
Pharmaceuticals. "We have now confirmed our ability to provide
commercial quality and quantity of monoclonal antibodies for human use.
It is important not only for this trial but gives us additional
assurance that we can do the same with other antibodies destined for
human trials and commercialization."
Actimab-A, Actinium's second program is continuing its clinical
development in a Phase 1/2 trial for newly diagnosed AML patients over
the age of 60 in a single arm multicenter trial. The Company expects to
make significant progress in the Phase 2 portion of the trial and
announce interim results in 2014. Actimab-A is being developed as a
first line therapy and has attracted support from some of the leading
experts at the most prestigious cancer treatment hospitals due to the
potential of its safety and efficacy profile.
Actimab-A consists of the Lintuzumab monoclonal antibody and actinium
225. Actnium-225 decays by giving off high-energy alpha particles,
which kill cancer cells. When actinium decays, it produces a series of
daughter atoms, each of which gives off its own alpha particle,
increasing the chances that the cancer cell will be destroyed.
Lintuzumab is the humanized version of M195 and is a monoclonal antibody
that targets CD33, found on myeloid leukemia cells. Both the alpha
particle technology and lintuzumab were initially developed at Memorial
Sloan Kettering Cancer Center.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based
biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's
targeted radiotherapy is based on its proprietary delivery platform for
the therapeutic utilization of alpha-emitting actinium-225 and
bismuth-213 and certain beta emitting radiopharmaceuticals in
conjunction with monoclonal antibodies. The Company's lead
radiopharmaceutical Iomab™-B will be used in preparing patients for
hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. The Company is preparing a single, pivotal, multicenter
Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute
Myeloid Leukemia (AML) patients over the age of 55 with a primary
endpoint of durable complete remission. The company's second program,
Actimab-A, is continuing its clinical development in a Phase 1/2 trial
for newly diagnosed AML patients over the age of 60 in a single-arm
multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.
For more information:
Visit our web site www.actiniumpharmaceuticals.com
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements
are based on management's current expectations and involve risks and
uncertainties, which may cause actual results to differ materially from
those set forth in the statements. The forward-looking statements may
include statements regarding product development, product potential, or
financial performance. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected. Actinium
Pharmaceuticals undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
[ Back To NFVZone's Homepage ]